Intracellular News and Research

RSS

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Research at the Babraham Institute, investigating how white blood cells known as B cells develop, has revealed that genes from the Phosphatidylinositol 3-kinase family of enzymes are critical in enabling the B cells to produce antibodies in the spleen and lymph nodes.

10 Aug 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.

10 Aug 2010

Scientists identify new targets to develop treatment for HD

Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington's disease. These enzymes, matrix metalloproteinases, provide new targets for drug therapies for the disease - targets that have already been shown to respond to cancer drugs currently in clinical development.

29 Jul 2010

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.

29 Jul 2010

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Using chemical "nanoblasts" that punch tiny holes in the protective membranes of cells, researchers have demonstrated a new technique for getting therapeutic small molecules, proteins and DNA directly into living cells.Carbon nanoparticles activated by bursts of laser light trigger the tiny blasts, which open holes in cell membranes just long enough to admit therapeutic agents contained in the surrounding fluid. By adjusting laser exposure, the researchers administered a small-molecule marker compound to 90 percent of targeted cells - while keeping more than 90 percent of the cells alive.

28 Jul 2010

NIH awards BU $1.6M grant to target protein-protein interactions with synthetic organic drugs

An interdisciplinary team of Boston University professors is launching a project to develop new ways to target protein-protein interactions with synthetic organic drugs. Financed by a four-year $1.6 million grant from the National Institutes of Health, the goal is to develop new approaches for discovering "drug-like" small molecule inhibitors against challenging protein-protein interaction (PPI) interfaces.

27 Jul 2010

IAS announces recipients of CNIHR grants

The International AIDS Society today announced the recipients of its first joint research grant programme, Creative and Novel Ideas in HIV Research. CNIHR grants, funded in partnership with the U.S. National Institutes of Health and the NIH-supported Centers for AIDS Research are designed to promote innovative research and new ideas from early stage investigators whose primary focus has previously been in fields of scientific inquiry other than HIV/ AIDS.

14 Jul 2010

New study on impact of bortezomib on mantle cell lymphoma

A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE-), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib.

13 Jul 2010

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

A team of bioengineers from the University of Pennsylvania Institute for Medicine and Engineering have trained a computer neural network model to accurately predict how blood platelets would respond to complex conditions found during a heart attack or stroke.

21 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

In diverse neurodegenerative diseases ranging from Parkinson's to Alzheimer's, researchers have long noted accumulations of a little-understood neuronal protein called α-synuclein. Pathological and genetic evidence strongly suggested that excessive α-synuclein played a role in the evolution of these diseases, but it was unclear how too much α-synuclein culminated in synaptic damage and neurodegeneration.

17 Jun 2010

Copy number variants may cause autism: Study

An international consortium of researchers from more than 70 universities, including the University of Utah, has reported that a study of nearly 2,300 people supports the growing consensus that autism is caused in part by rare genetic changes called copy number variants (CNVs).

10 Jun 2010

New genetic discoveries from Autism Genome Project

An international consortium of researchers working under the auspices of Autism Speaks, the world's largest autism science and advocacy organization, has announced new genetic discoveries from the second phase of its collaborative study: the Autism Genome Project. The results were published today in the journal Nature, one of the world's most respected peer-reviewed scientific publications.

10 Jun 2010

Autism is caused in part by CNVs: Study

10 Jun 2010

Boosting levels of ABCG1 protein in diabetics will improve insulin production

If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, who led the team, which included researchers from the University of Virginia.

8 Jun 2010

La Jolla Institute scientist finds protein key to insulin secretion

8 Jun 2010

Celera applies CE mark to real-time PCR test for detection of variant in KIF6 gene

Celera Corporation today announced that it has signed a Declaration of Conformity and applied the CE mark to a real-time PCR (polymerase chain reaction) test for detection of a variant in the KIF6 gene, allowing the test to be marketed in the European Union and other geographic areas that recognize the CE Mark.

7 Jun 2010

MSKCC researchers study novel approach to treat metastatic melanoma

Physician-scientists at Memorial Sloan-Kettering Cancer Center are studying a novel approach to treat metastatic melanoma, known as immunotherapy, which uses the body's own immune system to attack cancer. Presented today at the American Society of Clinical Oncology annual meeting, encouraging new data shows - for the first time - a survival benefit in metastatic melanoma patients using an immunotherapy discovered and clinically investigated by researchers at Memorial Sloan-Kettering.

7 Jun 2010

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.

2 Jun 2010

TQ can suppress growth of aggressive PCa cell lines: Researchers

Researchers at the Tulane University School of Medicine, in New Orleans, LA, have demonstrated that thymoquinone a major component of black seed oil (Nigella sativa) can suppress the growth of several aggressive prostate cancer cell lines, in vitro. Although previous studies have shown the anti-proliferative effects of TQ in different types of cancers, the molecular mechanism of this effect of TQ had not been delineated.

2 Jun 2010

Intracellular News and Research

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Scientists identify new targets to develop treatment for HD

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

NIH awards BU $1.6M grant to target protein-protein interactions with synthetic organic drugs

IAS announces recipients of CNIHR grants

New study on impact of bortezomib on mantle cell lymphoma

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

Copy number variants may cause autism: Study

New genetic discoveries from Autism Genome Project

Autism is caused in part by CNVs: Study

Boosting levels of ABCG1 protein in diabetics will improve insulin production

La Jolla Institute scientist finds protein key to insulin secretion

Celera applies CE mark to real-time PCR test for detection of variant in KIF6 gene

MSKCC researchers study novel approach to treat metastatic melanoma

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

TQ can suppress growth of aggressive PCa cell lines: Researchers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News